
    
      This study will collect clinical data, mainly focused on safety, in Korean population as per
      the requirement of KFDA for market authorization.

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship.
    
  